Erika Mehl

Erika Mehl

UNVERIFIED PROFILE

Are you Erika Mehl?   Register this Author

Register author
Erika Mehl

Erika Mehl

Publications by authors named "Erika Mehl"

Are you Erika Mehl?   Register this Author

9Publications

224Reads

37Profile Views

An international Ki67 reproducibility study.

J Natl Cancer Inst 2013 Dec 7;105(24):1897-906. Epub 2013 Nov 7.

Affiliations of authors: Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD (MCP, LMM); Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada (SCYL, DG, EM, TON); Department of Laboratory Medicine and Pathology, University of Alberta, Alberta, Canada (JCH); Division of Pathology and Laboratory Medicine, European Institute of Oncology, Milan, Italy (MGM); Division of Pathology and Laboratory Medicine, European Institute of Oncology, and University of Milan, Milan, Italy (GV); Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom (LAZ); Department of Pathology, Centre Jean Perrin, Clermont-Ferrand, and Université d'Auvergne, France (FP-L); Transformative Pathology, Ontario Institute for Cancer Research, Toronto, Ontario, Canada (JMSB); PhenoPath Laboratories, Seattle, WA (AMG); Department of Pathology, MD Anderson Cancer Center, Houston, TX (WFS); Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, United Kingdom (TP); The EMMES Corporation, Rockville, MD (RAE); Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI (DFH); Academic Department of Biochemistry, Royal Marsden Hospital, London, United Kingdom (MD); on behalf of the International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888090PMC
December 2013

Calculator for ovarian carcinoma subtype prediction.

Mod Pathol 2011 Apr 3;24(4):512-21. Epub 2010 Dec 3.

Genetic Pathology Evaluation Centre, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2010.215DOI Listing
April 2011

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

Breast Cancer Res Treat 2010 Jan 10;119(1):53-61. Epub 2009 Feb 10.

Genetic Pathology Evaluation Centre at Vancouver General Hospital, Prostate Center, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-009-0318-0DOI Listing
January 2010

Validation of immature adipogenic status and identification of prognostic biomarkers in myxoid liposarcoma using tissue microarrays.

Hum Pathol 2009 Sep 14;40(9):1244-51. Epub 2009 Apr 14.

Vancouver Coastal Health Research Institute and University of British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2009.01.011DOI Listing
September 2009

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype.

Mod Pathol 2009 Mar 9;22(3):469-75. Epub 2009 Jan 9.

Department of Pathology, Genetic Pathology Evaluation Centre of the Prostate Research Centre, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2008.206DOI Listing
March 2009

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies.

PLoS Med 2008 Dec;5(12):e232

Department of Pathology, Genetic Pathology Evaluation Centre of the Prostate Research Centre, Vancouver General Hospital and British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pmed.0050232DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2592352PMC
December 2008

Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma.

BMC Med 2007 Nov 15;5:33. Epub 2007 Nov 15.

Molecular Oncology and Breast Cancer Program, British Columbia Cancer Research Centre and Department of Pathology, University ofBritish Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-5-33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2200658PMC
November 2007